The Korea Atomic Energy Research Institute (KAERI) completed the High-flux Advanced Neutron Application Reactor (HANARO) in 1995 and the radioisotope production facilities (RIPF) in 1997. Many devices and handling tools were developed and applied for the production of radioisotopes. Emphasis on RI production plan was placed on the development of new radiopharmaceuticals, the development of new radiation sources for industrial use and the steady production of selected radioisotopes. The selected items are 166{sup left}Ho-based pharmaceuticals, fission 99{sup left}Mo/(99m){sup left}Tc generators, and products of 131{sup left}I and 192{sup left}Ir and 60{sup left}Co sources for industrial use. Now KAERI regularly produces radioisotopes (131{sup left}I, (99m) {sup left}Tc, 166{sup left}Ho, 192{sup left}Ir, 60{sup left}Co etc.) and labeled compounds including (99m) {sup left}Tc cold kits. Newly developed therapeutic agents are a 166{sup left}Ho-chitosan complex for liver cancer treatment, a 166{sup left}Ho patch for skin cancer treatment and devices such as the stent and balloon for the prevention against restenosis of the coronary artery. Feasibility studies on the installation of a (99m) {sup left}Tc generator loading facility and on 60{sup left}Co production for food irradiation were finished. The 192{sup left}Ir sealed source assembly for NDT has been supplied to domestic users since May 2001. The fission moly process, separation process of non-sealed sources (125{sup left}I, 33{sup left}P, 89{sup left}Sr, 153{sup left}Sm, 188{sup left}Re) and fabrication process of sealed sources (169{sup left}Yb, 75{sup left}Se) are also under development. For the quality assurance of our final products, we obtained ISO certification in 2000. We are carrying out a feasibility study on a new research reactor for the stable supply of radioisotopes in Korea.
展开▼
